Promising cocktail of targeted drugs and chemo takes on mantle cell lymphoma
NCT ID NCT03710772
First seen Nov 06, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This phase II trial is testing a combination of targeted drugs (ibrutinib, rituximab, venetoclax) plus chemotherapy in 51 newly diagnosed young adults with mantle cell lymphoma. The goal is to see if this approach can achieve a complete response—meaning no signs of cancer—after treatment. The study is active but no longer recruiting, and researchers are closely monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ibrutinib, rituximab, venetoclax, and combination chemotherapy (cyclophosphamide, vincristine, doxorubicin, dexamethasone)
What this could lead to
If successful, this combination could become a more effective first-line treatment for young patients with mantle cell lymphoma, potentially leading to longer remission and better disease control.
What could go wrong
This is a small phase II trial (51 participants) with no control group, so results may not apply broadly. The aggressive chemotherapy carries significant side effects, and the long-term safety and efficacy are still unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.